New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 18, 2014
16:10 EDTAERIAerie Pharmaceuticals reports Q4 GAAP EPS (62c), consensus (25c)
Included in the $10.3M net loss and the (62c) EPS are non-cash charges totaling $4.9M, of which $1.3M represents stock-based compensation expense included in operating expenses. With these non-cash items excluded, the adjusted operating expenses of $5.4M include adjusted research and development expenses of $3.0M and adjusted general and administrative expenses of $2.4M. In addition to the $1.3M stock-based compensation expense, the $4.9M in non-cash charges include a $2.7M extinguishment loss related to the conversion of the Company’s outstanding convertible promissory notes to common equity upon the closing of the IPO and $900,000 in accrued interest and amortization expense related to the Company’s notes that were converted to common equity upon the closing of the IPO.
News For AERI From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
March 25, 2015
10:00 EDTAERIOn The Fly: Analyst Initiation Summary
Subscribe for More Information
March 24, 2015
16:06 EDTAERIAerie Pharmaceuticals initiated with a Buy at Brean Capital
Subscribe for More Information
06:02 EDTAERIAerie Pharmaceuticals completes enrollment for Phase 3 trial of Rhopressa
Aerie Pharmaceuticals announced the completion of enrollment in the Company’s second Phase 3 registration trial of Rhopressa, a novel once-daily, triple-action eye drop being tested for its ability to lower intraocular pressure,or IOP, in patients with glaucoma or ocular hypertension. Rocket 2 will measure efficacy over three months, as well as safety over one year. The primary efficacy endpoint of the trial is to demonstrate non-inferiority of IOP lowering for Rhopressa compared to timolol.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use